Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB006 in Healthy Volunteers
NCT04920786Phase 1Completed
- Sponsor
- TrueBinding Inc.
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing TB006 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events, Pharmacokinetic Profile and 1 more. Started Jun 2021; status: completed.
02
Drugs
TB006
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04920786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920786.